Dr. Lim will provide an overview of the MiMedx research study published in the Journal of Biomedical Materials Research that evaluated dHUC and its biological properties. It was the first published characterization of dHUC tissue.

During a sponsored hands-on workshop on November 8, David Kyle, DPM, will present "Application Techniques and Therapeutic Approaches Using EpiFix, EpiCord & AmnioFix Allografts for Wound Healing and Surgical Procedures". MiMedx will also sponsor a workshop during the Amputation/ Limb Salvage Continuum of Care Skills course on November 10.

The five poster abstracts will report on MiMedx EpiFix and EpiCord allografts, as follows:

MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.3 million allografts to date. For additional information, please visit www.mimedx.com.